Brought to you by 
Lilly joins ICAgen-Sphinx ion channel screening agreement
31 Aug 2020
Executive Summary
Ion channel biotech company ICAgen has expanded its April 1993 drug discovery agreement with Sphinx Pharmaceuticals to bring Sphinx's new owner Eli Lilly into the deal.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly joins ICAgen-Sphinx ion channel screening agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice